Witnessing the stock’s movement on the chart, on Wednesday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) had a quiet start as it plunged -5.05% to $14.85, before settling in for the price of $15.64 at the close. Taking a more long-term approach, DAWN posted a 52-week range of $10.90-$18.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 0.00%. Meanwhile, its Annual Earning per share during the time was -84.59%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 68.09%. This publicly-traded company’s shares outstanding now amounts to $87.23 million, simultaneously with a float of $68.17 million. The organization now has a market capitalization sitting at $1.50 billion. At the time of writing, stock’s 50-day Moving Average stood at $14.45, while the 200-day Moving Average is $14.67.
Day One Biopharmaceuticals Inc (DAWN) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Day One Biopharmaceuticals Inc’s current insider ownership accounts for 32.40%, in contrast to 65.61% institutional ownership. According to the most recent insider trade that took place on Nov 08 ’24, this organization’s HEAD OF R&D sold 18,255 shares at the rate of 16.17, making the entire transaction reach 295,229 in total value, affecting insider ownership by 1,067,535. Preceding that transaction, on Nov 11 ’24, Company’s HEAD OF R&D sold 10,000 for 16.10, making the whole transaction’s value amount to 160,994. This particular insider is now the holder of 1,057,535 in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Revenue Records
Day One Biopharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 68.09% and is forecasted to reach -1.00 in the upcoming year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Let’s observe the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). It’s Quick Ratio in the last reported quarter now stands at 14.55. The Stock has managed to achieve an average true range (ATR) of 0.78. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 14.69.
In the same vein, DAWN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.01, a figure that is expected to reach -0.46 in the next quarter, and analysts are predicting that it will be -1.00 at the market close of one year from today.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Going through the that latest performance of [Day One Biopharmaceuticals Inc, DAWN]. Its last 5-days volume of 1.34 million indicated improvement to the volume of 0.96 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 48.25% While, its Average True Range was 0.82.
Raw Stochastic average of Day One Biopharmaceuticals Inc (DAWN) in the period of the previous 100 days is set at 54.85%, which indicates a major rise in contrast to 30.04% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 36.68% that was lower than 41.27% volatility it exhibited in the past 100-days period.
